SAROJASpecialty Chemicals
Saroja Pharma Indus Ind L — Profit & Loss Statement
₹28.00
+0.00%
Saroja Pharma Indus Ind L Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | 40.67 Cr | 50.19 Cr | 55.63 Cr | 36.66 Cr |
| Tax Effect Of Unusual Items | -4902.99 | -2600.13 | -9662.51 | -1994.88 |
| Tax Rate For Calcs | 0.27 | 0.29 | 0.28 | 0.28 |
| Normalized EBITDA | 2.58 Cr | 2.55 Cr | 2.29 Cr | 1.32 Cr |
| Total Unusual Items | -18000.00 | -9000.00 | -35000.00 | -7000.00 |
| Total Unusual Items Excluding Goodwill | -18000.00 | -9000.00 | -35000.00 | -7000.00 |
| Net Income From Continuing Operation Net Minority Interest | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Reconciled Depreciation | 0.09 Cr | 0.07 Cr | 0.05 Cr | 0.02 Cr |
| Reconciled Cost Of Revenue | 35.64 Cr | 45.30 Cr | 50.32 Cr | 33.34 Cr |
| EBITDA | 2.58 Cr | 2.55 Cr | 2.29 Cr | 1.32 Cr |
| EBIT | 2.49 Cr | 2.49 Cr | 2.25 Cr | 1.30 Cr |
| Net Interest Income | -1.43 Cr | -1.31 Cr | -0.79 Cr | -0.33 Cr |
| Interest Expense | 1.28 Cr | 1.00 Cr | 0.67 Cr | 0.27 Cr |
| Interest Income | 0.02 Cr | 0.01 Cr | 95000.00 | 41000.00 |
| Normalized Income | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Net Income From Continuing And Discontinued Operation | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Total Expenses | 38.20 Cr | 47.54 Cr | 53.57 Cr | 35.38 Cr |
| Rent Expense Supplemental | 0.08 Cr | 0.10 Cr | 0.08 Cr | 0.05 Cr |
| Diluted NI Availto Com Stockholders | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Net Income Common Stockholders | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.73 Cr |
| Net Income Including Noncontrolling Interests | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.74 Cr |
| Net Income Continuous Operations | 0.88 Cr | 1.06 Cr | 1.14 Cr | 0.74 Cr |
| Tax Provision | 0.33 Cr | 0.43 Cr | 0.44 Cr | 0.30 Cr |
| Pretax Income | 1.21 Cr | 1.49 Cr | 1.58 Cr | 1.04 Cr |
| Other Non Operating Income Expenses | 0.14 Cr | 0.06 Cr | 0.16 Cr | 0.07 Cr |
| Special Income Charges | -18000.00 | -9000.00 | -35000.00 | -7000.00 |
| Write Off | 18000.00 | 9000.00 | 35000.00 | 7000.00 |
| Net Non Operating Interest Income Expense | -1.43 Cr | -1.31 Cr | -0.79 Cr | -0.33 Cr |
| Total Other Finance Cost | 0.17 Cr | 0.32 Cr | 0.14 Cr | 0.07 Cr |
| Interest Expense Non Operating | 1.28 Cr | 1.00 Cr | 0.67 Cr | 0.27 Cr |
| Interest Income Non Operating | 0.02 Cr | 0.01 Cr | 95000.00 | 41000.00 |
| Operating Income | 2.47 Cr | 2.65 Cr | 2.06 Cr | 1.28 Cr |
| Operating Expense | 2.56 Cr | 2.24 Cr | 3.25 Cr | 2.04 Cr |
| Other Operating Expenses | 0.52 Cr | 0.46 Cr | 1.72 Cr | 0.94 Cr |
| Depreciation And Amortization In Income Statement | 0.09 Cr | 0.07 Cr | 0.05 Cr | 0.02 Cr |
| Depreciation Income Statement | 0.09 Cr | 0.07 Cr | 0.04 Cr | 0.02 Cr |
| Selling General And Administration | 0.40 Cr | 0.24 Cr | 0.26 Cr | 0.17 Cr |
| Selling And Marketing Expense | 0.10 Cr | 0.11 Cr | 0.12 Cr | 0.10 Cr |
| General And Administrative Expense | 0.30 Cr | 0.13 Cr | 0.14 Cr | 0.07 Cr |
| Rent And Landing Fees | 0.08 Cr | 0.10 Cr | 0.08 Cr | 0.05 Cr |
| Gross Profit | 5.03 Cr | 4.90 Cr | 5.31 Cr | 3.32 Cr |
| Cost Of Revenue | 35.64 Cr | 45.30 Cr | 50.32 Cr | 33.34 Cr |
| Operating Revenue | 40.67 Cr | 50.19 Cr | 55.63 Cr | 36.66 Cr |
| Diluted Average Shares | — | 0.40 Cr | 0.40 Cr | 0.40 Cr |
| Basic Average Shares | — | 0.40 Cr | 0.40 Cr | 0.40 Cr |
| Diluted EPS | — | 2.64 | 2.84 | 1.82 |
| Basic EPS | — | 2.64 | 2.84 | 1.82 |
| Amortization | — | 12000.00 | 37000.00 | 19000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Saroja Pharma Indus Ind L
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.